Year-end Sale % OFF 
Abstract
To design a multi-epitope assembly peptide (MEP) of Acinetobacter baumannii and evaluate its immunogenicity and protective immunity in Balb/c mice. The T- and B-cell epitopes of outer membrane proteins FilF and NucAb from A. baumannii were predicted and identified by using bioinformatics software and immunological tests. Peptides with predicted high adhesin probability from A. baumannii Ata protein was used as the backbone, two B-cell epitopes and one CD4+ T-cell epitope from FilF were linked to the N-terminal of the backbone, and two B-cell epitopes and one CD4+ T-cell epitope from NucAb were linked to the C-terminal of the backbone to construct the MEP. The gene of the MEP was expressed in E. coli BL21, and its immunogenicity and protective efficacy were evaluated in Balb/c mice. A recombinant protein with a molecular weight of about 37 kDa was successfully purified, and was identified as the recombinant multi-epitope assembly peptide (rMEP) by Western blot analysis. The animal tests showed that the rMEP was highly immunogenic and could induce high levels of IgG antibody and provide potent protection (88.9%) against lethal doses of A. baumannii. This is the first report of the design and study of a rMEP vaccine against A. baumannii. The results indicate that the rMEP is a promising vaccine candidate for the control of infections caused by A. baumannii.
Highlights
Acinetobacter baumannii is a common conditional pathogenic bacterium which mainly causes hospital infections, such as intubation-associated pneumonia, traumatic infections, urogenital infections and catheter related sepsis [1, 2]
This is the first report of the design and study of a recombinant multi-epitope assembly peptide (rMEP) vaccine against A. baumannii
The results indicate that the rMEP is a promising vaccine candidate for the control of infections caused by A. baumannii
Summary
Acinetobacter baumannii is a common conditional pathogenic bacterium which mainly causes hospital infections, such as intubation-associated pneumonia, traumatic infections, urogenital infections and catheter related sepsis [1, 2]. Animal studies showed that some single recombinant protein based vaccines provided only partial protection against A. baumannii challenge, especially for heterogeneous bacterial strains, the vaccine design needs to be optimised further [8, 9]. Many new approaches to vaccine design have emerged, including the multi-epitope assembly peptide (MEP), which contains B-cell epitopes, T-cell epitopes or other specific residues from several different proteins. This kind of vaccine has been proved effective for the control of several other pathogens in animal models [10, 11]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
